Literature DB >> 17236903

Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.

T Andrew Burrow1, Mitchell B Cohen, Ronald Bokulic, Gail Deutsch, Arabinda Choudhary, Richard A Falcone, Gregory A Grabowski.   

Abstract

A 5-year-old male with Gaucher's disease type 3 developed progressive mesenteric and mediastinal lymphadenopathy over 12 months, despite enzyme replacement therapy, contributing to the development of a protein-losing enteropathy. These complications are unique, indicating poorly accessible, differentially responsive compartments in patients with Gaucher's disease who are receiving enzyme therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236903     DOI: 10.1016/j.jpeds.2006.10.062

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

2.  Pulmonary hemorrhage in type 3 Gaucher disease: a case report.

Authors:  Ashok Vellodi; Michael Ashworth; Niamh Finnegan; Colin Wallis
Journal:  J Inherit Metab Dis       Date:  2010-08-06       Impact factor: 4.982

3.  Velaglucerase alfa in the treatment of Gaucher disease type 1.

Authors:  Thomas A Burrow; Gregory A Grabowski
Journal:  Clin Investig (Lond)       Date:  2011-02

4.  CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.

Authors:  Thomas A Burrow; Ying Sun; Carlos E Prada; Laurie Bailey; Wujuan Zhang; Amanda Brewer; Steve W Wu; Kenneth D R Setchell; David Witte; Mitchell B Cohen; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2014-09-02       Impact factor: 4.797

Review 5.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

6.  Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse.

Authors:  Ying Sun; Huimin Ran; Benjamin Liou; Brian Quinn; Matt Zamzow; Wujuan Zhang; Jacek Bielawski; Kazuyuki Kitatani; Kenneth D R Setchell; Yusuf A Hannun; Gregory A Grabowski
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

7.  Gaucher Disease with Mesenteric Lymphadenopathy: A Case with 13-year Follow-up.

Authors:  Zi-Xing Ye; Xiang Gao; Qiang Qu; Xin Ye; Xiao-Dong He
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

8.  Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease.

Authors:  A A Mhanni; M Kozenko; J N Hartley; M Deneau; W El-Matary; C Rockman-Greenberg
Journal:  Mol Genet Metab Rep       Date:  2015-12-29

9.  Very rare condition of multiple Gaucheroma: A case report and review of the literature.

Authors:  Szu-Yin Tseng; Dau-Ming Niu; Tzu-Hung Chu; Yi-Chen Yeh; Man-Hsu Huang; Tsui-Feng Yang; Hsuan-Chieh Liao; Chuan-Chi Chiang; Hui-Chen Ho; Wen-Jue Soong; Chia-Feng Yang
Journal:  Mol Genet Metab Rep       Date:  2019-05-09

10.  Very rare condition of multiple Gaucheroma: A case report and review of the literature.

Authors:  Szu-Yin Tseng; Dau-Ming Niu; Tzu-Hung Chu; Yi-Chen Yeh; Man-Hsu Huang; Tsui-Feng Yang; Hsuan-Chieh Liao; Chuan-Chi Chiang; Hui-Chen Ho; Wen-Jue Soong; Chia-Feng Yang
Journal:  Mol Genet Metab Rep       Date:  2019-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.